Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a product-oriented drug delivery company focused on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. Since our inception in 1995, we have established a successful track record and maintain partnerships with large and small biotech and pharma companies throughout the world.
Our business activities include formulation development services, drug delivery technologies and controlled release product development.
OctoPlus uses its proprietary drug delivery technologies to develop controlled release products for clients.
OctoPlus has developed a number of proprietary drug delivery technologies that facilitate the controlled release of biologically active compounds. Our three main technology platforms enable us to develop tailor-made controlled release formulations for all classes of injectable drug compounds:
OctoDEX®: a dextran-based microsphere delivery technology for proteins and particulate systems.
PolyActive®: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.
SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV).
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What would you say was…
Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of…
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
See our Cookie Privacy Policy Here